HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer

por Olson, Devra, Taylor, Janelle, Willis, Kelsi, Hensley, Kelly, Allred, Sean, Zaval, Margo, Farr, Lauren, Thurman, Robert, Jain, Nishi, Hein, Renee, Ulrich, Michelle, Peterson, Scott, Kulukian, Anita
Publicado 2023

SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models

por Gray, Elizabeth, Ulrich, Michelle, Epp, Angela, Younan, Patrick, Sahetya, Disha, Hensley, Kelly, Allred, Sean, Huang, Li-Ya, Hahn, Julie, Gahnberg, Kristen, Treuting, Piper M, Trueblood, Esther S, Gosink, John J, Thurman, Robert, Wo, Serena, Spahr, Kellie, Haass, Evgenia Jane, Snead, Katie, Miller, Dannah, Padilla, Mary, Smith, Alyson J, Frantz, Chris, Schrum, Jason P, Nazarenko, Natalya, Gardai, Shyra J
Publicado 2023